Zatosetron maleate | CAS#123482-23-5

MedKoo Cat#: 529176 | Name: Zatosetron maleate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zatosetron maleate is an antimigraine.

Chemical Structure

Zatosetron maleate

CAS#123482-23-5

Theoretical Analysis

MedKoo Cat#: 529176

Name: Zatosetron maleate

CAS#: 123482-23-5

Chemical Formula: C23H29ClN2O6

Exact Mass: 464.1714

Molecular Weight: 464.94

Elemental Analysis: C, 59.42; H, 6.29; Cl, 7.62; N, 6.03; O, 20.65

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Zatosetron maleate

IUPAC/Chemical Name

7-Benzofurancarboxamide, 2,3-dihydro-5-chloro-2,2-dimethyl-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-, (Z)-2-butenedioate (1:1)

InChi Key

HAFQATMFFHYNPN-BTJKTKAUSA-N

InChi Code

InChI=1S/C19H25ClN2O2.C4H4O4/c1-19(2)10-11-6-12(20)7-16(17(11)24-19)18(23)21-13-8-14-4-5-15(9-13)22(14)3;5-3(6)1-2-4(7)8/h6-7,13-15H,4-5,8-10H2,1-3H3,(H,21,23);1-2H,(H,5,6)(H,7,8)/b;2-1-

SMILES Code

O=C(C1=C(OC(C)(C)C2)C2=CC(Cl)=C1)NC3CC(N4C)CCC4C3.O=C(O)/C=C\C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 464.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Maksay G, Bíró T, Laube B, Nemes P. Hyperekplexia mutation R271L of alpha1 glycine receptors potentiates allosteric interactions of nortropeines, propofol and glycine with [3H]strychnine binding. Neurochem Int. 2008 Jan;52(1-2):235-40. Epub 2007 Jun 21. PubMed PMID: 17655979. 2: Maksay G, Bíró T. Dual cooperative allosteric modulation of binding to ionotropic glycine receptors. Neuropharmacology. 2002 Dec;43(7):1087-98. Erratum in: Neuropharmacology. 2003 May;44(6):843. PubMed PMID: 12504915. 3: Shannon HE, Lutz EA. Yohimbine produces antinociception in the formalin test in rats: involvement of serotonin(1A) receptors. Psychopharmacology (Berl). 2000 Mar;149(1):93-7. PubMed PMID: 10789888. 4: Zatosetron. (LY 191617, LY 277359). Drugs R D. 1999 Dec;2(6):397-9. PubMed PMID: 10763451. 5: Zatosetron. LY 191617, LY 277359. Drugs R D. 1999 Oct;2(4):253-5. PubMed PMID: 10659404. 6: Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31. PubMed PMID: 10211913. 7: Maksay G. Bidirectional allosteric modulation of strychnine-sensitive glycine receptors by tropeines and 5-HT3 serotonin receptor ligands. Neuropharmacology. 1998 Dec;37(12):1633-41. PubMed PMID: 9886686. 8: Espey MJ, Du HJ, Downie JW. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res. 1998 Jul 6;798(1-2):101-8. PubMed PMID: 9666094. 9: Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl). 1997 Jan;129(1):79-84. PubMed PMID: 9122367. 10: Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm. 1996 Oct;24(5):461-73. Review. PubMed PMID: 9131485. 11: Espey MJ, Downie JW. Serotonergic modulation of cat bladder function before and after spinal transection. Eur J Pharmacol. 1995 Dec 12;287(2):173-7. PubMed PMID: 8749032. 12: Toral J, Hu W, Critchett D, Solomon AJ, Barrett JE, Sokol PT, Ziai MR. 5-HT3 receptor-independent inhibition of the depolarization-induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron. J Pharm Pharmacol. 1995 Jul;47(7):618-22. PubMed PMID: 8568632. 13: Gidda JS, Evans DC, Cohen ML, Wong DT, Robertson DW, Parli CJ. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs. J Pharmacol Exp Ther. 1995 May;273(2):695-701. PubMed PMID: 7752072. 14: Bendele A, Means J, Shoufler J, Schmalz C, Hanasono G, Symanowski J, Adams E. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys. Drug Chem Toxicol. 1995 Feb;18(1):61-82. PubMed PMID: 7768200. 15: Banner SE, Sanger GJ. Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity. Br J Pharmacol. 1995 Jan;114(2):558-62. PubMed PMID: 7881756; PubMed Central PMCID: PMC1510257. 16: Miyata K, Honda K. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles]. Nihon Yakurigaku Zasshi. 1994 Sep;104(3):143-52. Review. Japanese. PubMed PMID: 7959407. 17: Ring BJ, Parli CJ, George MC, Wrighton SA. In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. Drug Metab Dispos. 1994 May-Jun;22(3):352-7. PubMed PMID: 8070310. 18: Bendele AM, Buenger DA, McGrath JP, Schmalz CA, Hanasono GK. Chronic toxicity, metabolism, and pharmacokinetics of the 5-HT3 receptor antagonist zatosetron (LY277359) in Fischer 344 rats. Fundam Appl Toxicol. 1994 May;22(4):494-504. PubMed PMID: 8056197. 19: Chappell AS, Bay JM, Botzum GD, Cohen ML. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine. Neuropharmacology. 1994 Mar-Apr;33(3-4):509-13. PubMed PMID: 7984290. 20: Schwartz SM, Goldberg MJ, Gidda JS, Cerimele BJ. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. J Clin Pharmacol. 1994 Mar;34(3):250-4. PubMed PMID: 7517409.